QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
OTCMKTS:ENDV

Endonovo Therapeutics (ENDV) Stock Forecast, Price & News

$0.01
0.00 (-0.67%)
(As of 01:00 PM ET)
Compare
Today's Range
$0.0148
$0.0149
50-Day Range
$0.01
$0.0199
52-Week Range
$0.00
$0.03
Volume
13,784 shs
Average Volume
353,251 shs
Market Capitalization
$4.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ENDV stock logo

About Endonovo Therapeutics (OTCMKTS:ENDV) Stock

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development, manufacture, and distribution of medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, and SofPulse Electroceutical Therapy. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

Receive ENDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENDV Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
ENDV.PK - | Stock Price & Latest News | Reuters
New Details on Endonovo’s Spin-Off of SofPulse, Inc.
Endonovo Launches Telehealth Initiative
Endonovo Therapeutics Issues Corporate Update
Acrivon Therapeutics sets IPO price range
See More Headlines
Receive ENDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENDV Company Calendar

Today
5/31/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ENDV
Employees
1
Year Founded
N/A

Profitability

Net Income
$-18,480,000.00
Net Margins
-3,988.29%
Pretax Margin
-3,988.29%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
($0.09) per share

Miscellaneous

Free Float
260,785,000
Market Cap
$4.11 million
Optionable
Not Optionable
Beta
0.25

Key Executives

  • Alan Brian Collier
    Chairman, CEO, CFO & Secretary
  • Don Calabria
    Vice President-Operations
  • Garry Michael Kann
    Head-Corporate Development
  • Ira Weisberg
    President-Medical Division
  • David Clark
    Vice President-Sales













ENDV Stock - Frequently Asked Questions

How have ENDV shares performed in 2023?

Endonovo Therapeutics' stock was trading at $0.0180 at the beginning of the year. Since then, ENDV shares have decreased by 17.3% and is now trading at $0.0149.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM).

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.01.

How much money does Endonovo Therapeutics make?

Endonovo Therapeutics (OTCMKTS:ENDV) has a market capitalization of $4.11 million and generates $140,000.00 in revenue each year.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The official website for the company is www.endonovo.com. The biotechnology company can be reached via phone at (800) 489-4774, via email at sbarnes@endonovo.com, or via fax at 818-230-9899.

This page (OTCMKTS:ENDV) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -